MOVEMENTUM

What this means for you

Approved and waiting on proof of use. It will register unless the applicant drops it, and its 17 Jan 2025 filing date already counts against anyone who files later.

Record

Serial number

99006194

Mark type

Stylized text

Filed

17 Jan 2025

Published for opposition

14 Oct 2025

Attorney of record

Rebecca Dalton

Goods and services

• Class 005 — Pharmaceuticals: Foods adapted for medical use and specially formulated to meet the dietary needs of patients and used under a physician's supervision; Pharmaceutical preparations for the treatment, prevention, and management of pain product and opioid use disorders and reducing and managing the dosing and usage of pain products and narcotics; Vitamin preparations; Pharmaceutical preparations for restoring and maintaining health and function in the presence of pain, physical discomfort, stiffness, sensitization, energy, arterial, venous, circulatory, cognitive, mental, central nervous system, autoimmune and mobility limitations; Pharmaceutical preparations for the treatment and management of pain, physical discomfort, sensitization, energy, arterial, venous, circulatory, stiffness, and mobility limitations; Nutritional Supplements; Pharmaceutical preparations for the treatment, management, and maintenance of physical function in neurological, musculoskeletal, cardiovascular, fibromyalgia, cognitive, central nervous system, mental, fatigue, autoimmune, inflammatory, and oxidative conditions, ailments and disorders; Dietary supplements; Pharmaceutical preparations for the treatment, prevention, and management of neurological, musculoskeletal, fibromyalgia, cardiovascular, cognitive, central nervous system, mental, fatigue, autoimmune, inflammatory, and oxidative conditions, ailments and disorders; Foods adapted for medical use and specially formulated to meet the dietary needs of patients and used under a physician's supervision as adjunctive therapies to drugs, biologics, medical devices, physical and occupational therapy, and other treatment modalities to improve neurological, musculoskeletal, cardiovascular, fibromyalgia, cognitive, central nervous system, mental, autoimmune, inflammatory, and oxidative conditions and ailments; Foods adapted for medical use and specially formulated to meet the dietary needs of patients and used under a physician's supervision in the treatment, prevention, and management of pain product and opioid use disorders and reducing and managing the dosing and usage of pain products and narcotics; Pharmaceutical preparations as adjunctive therapies to drugs, biologics, medical devices, physical and occupational therapy, and other treatment modalities to improve neurological, musculoskeletal, cardiovascular, fibromyalgia, cognitive, central nervous system, mental, autoimmune, inflammatory, and oxidative conditions and ailments

Owner

• Primus Pharmaceuticals, Inc., Scottsdale, AZ, US
• Primus Pharmaceuticals, Inc., Scottsdale, AZ, US

Prosecution history

• 09 Dec 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
• 14 Oct 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
• 14 Oct 2025 — PUBLISHED FOR OPPOSITION
• 08 Oct 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
• 16 Sept 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
• 16 Sept 2025 — EXAMINER'S AMENDMENT ENTERED
• 16 Sept 2025 — NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
• 16 Sept 2025 — EXAMINERS AMENDMENT E-MAILED
• 16 Sept 2025 — EXAMINERS AMENDMENT -WRITTEN
• 02 Jul 2025 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
• 02 Jul 2025 — NON-FINAL ACTION E-MAILED
• 02 Jul 2025 — NON-FINAL ACTION WRITTEN
• 26 Jun 2025 — ASSIGNED TO EXAMINER
• 17 Jan 2025 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
• 17 Jan 2025 — APPLICATION FILING RECEIPT MAILED